Premium
The effect of an ex vivo boosted immune cell therapy on canine atopic dermatitis: an open, uncontrolled pilot study
Author(s) -
Bae Seulgi,
Kim Kijung,
Oh Taeho
Publication year - 2018
Publication title -
veterinary dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.744
H-Index - 60
eISSN - 1365-3164
pISSN - 0959-4493
DOI - 10.1111/vde.12687
Subject(s) - ex vivo , medicine , immune system , in vivo , atopic dermatitis , adverse effect , cd8 , cytokine , flow cytometry , immunology , biology , microbiology and biotechnology
Background Canine atopic dermatitis (c AD ) is associated with an imbalance between multiple T lymphocytes and cytokines. Ex vivo boosted immune cell ( EBIC ) therapy is the sequential administration of ex vivo cultured and activated lymphocytes to patients to improve immune function. Objective This pilot study aimed to assess the safety of EBIC therapy and demonstrate its efficacy as a novel treatment for c AD . Animals Ten dogs with AD . Methods and materials The phenotypes of the immune cells before and after ex vivo culture were analysed by flow cytometry. EBIC s (1.0–5.0 × 10 8 cells/animal) were administered to dogs every two weeks, with a total of six injections. The c AD extent and severity index ( CADESI )‐03 and pruritus scores were calculated to evaluate the efficacy of EBIC therapy for c AD . For safety assessment, regular blood examination was conducted, and any adverse events recorded. The serum levels of interleukin ( IL )‐4, IL ‐10, IL ‐31 and interferon‐gamma ( IFN ‐γ) were evaluated. Results The cells expanded by an average of 57.52‐fold and the proportions of CD 8 + cells and IFN ‐γ‐producing cells significantly increased after ex vivo culture. Sequential EBIC therapy improved CADESI ‐03, and pruritus scores significantly. After stopping treatment the improvement rates increased for the CADESI score and were maintained for the pruritus score. There were no significant changes in cytokine levels. No significant adverse events were observed. Conclusions and clinical significance EBIC therapy is a safe and efficient treatment for c AD . This therapy could correct the immunological imbalance in dogs with AD by infusing activated T lymphocytes.